Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 plus toripalimab in advanced lung cancer
CTR20211998Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tifcemalimab, toripalimab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Aug 2021; status: completed.
02
Drugs
tifcemalimabtoripalimab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20211998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211998.